[New biological drugs in the treatment of inflammatory skin diseases].
Psoriasis in the only skin disease for which biological drug treatments are in use. Three of these are TNFalpha inhibitors and one, ustekinumab, is an inhibitor of the interleukins (IL) 12 and 23. The new IL-17 inhibitors have proven to be highly efficient, and new low molecular weight drugs such as Janus kinase inhibitors and phosphodiesterase 4 inhibitors may provide a competitive oral alternative to monoclonal antibodies. No biological drugs are available for atopic eczema. The pathogenesis of atopic eczema has, however become more precise, providing several interesting therapeutic targets in the future.
Tarja
T
Mälkönen
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D004485:Eczema / Q000188:drug therapy*; D006801:Humans; D018664:Interleukin-12 / Q000037:antagonists & inhibitors; D020381:Interleukin-17 / Q000037:antagonists & inhibitors; D053759:Interleukin-23 / Q000037:antagonists & inhibitors; D053612:Janus Kinases / Q000037:antagonists & inhibitors; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy*; D000069549:Ustekinumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D020381:Interleukin-17; D053759:Interleukin-23; D010726:Phosphodiesterase Inhibitors; D018664:Interleukin-12; D053612:Janus Kinases; D000069549:Ustekinumab